Unofficial Copy C3 1996 Regular Session 6lr0495

**By: Senators Bromwell, Young, Dorman, and Madden** Introduced and read first time: January 22, 1996 Assigned to: Finance

Committee Report: Favorable with amendments Senate action: Adopted Read second time: March 28, 1996

CHAPTER \_\_\_\_\_

1 AN ACT concerning

## 2 Experimental Medical Care Disclosure Act <u>Task Force on Emerging Medicaland</u> 3 Surgical Treatments

4 FOR the purpose of requiring certain health insurers to establish a certain process to 5 follow when evaluating emerging medical and surgical treatments for the purpose of 6 making coverage and payment decisions; requiring certain health insurers to make 7 certain disclosures to certain providers, enrollees, and prospectiveenrollees under 8 certain circumstances; specifying the provisions of the process; requiring certain 9 health insurers to identify certain local clinical experts to assist he health insurer in 10 evaluating emerging medical and surgical treatments; requiring certain health 11 insurers to file a certain report with the Insurance Commissioner; specifying the 12 contents of the report; prohibiting certain health insurers from preventing providers 13 from disclosing certain information to enrollees; prohibiting certain health insurers for certain purposes from conditioning the payment of the salary of an employee or 14 15 provider on the number or kind of health care services denied to enrollees; 16 specifying the application of this Act; authorizing the Insurance Commissioner to 17 adopt regulations; defining certain terms; and generally relating torequiring certain 18 health insurers to establish and follow a certain process when evaluating emerging medical and surgical treatments for the purpose of making certain coverage and 19 20 payment conditions establishing a Task Force on Emerging Medical andSurgical 21 Treatments; specifying the membership of the Task Force; providing for the 22 termination of this Act; and generally relating to emerging medical and surgical 23 treatments.

24 BY adding to

25 Article 48A - Insurance Code

26 Section 490FF

27 Annotated Code of Maryland

1	(1994 Replacement Volume and 1995 Supplement)		
2	SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF		
_	MARYLAND, That the Laws of Maryland read as follows:		
3	MARTLAND, That the Laws of Maryland fead as follows.		
4	Article 48A – Insurance Code		
5	490FF.		
6	(A) (1) IN THIS SECTION THE FOLLOWING WORDS HAVE THE MEANINGS		
7	INDICATED.		
8	<del>(2) "CARRIER" MEANS:</del>		
9	(I) AN INSURER;		
10			
10	(II) A NONPROFIT HEALTH SERVICE PLAN;		
1.1			
11	(III) A DENTAL PLAN ORGANIZATION; OR		
10			
12	(IV) ANY PERSON OR ENTITY ACTING AS A THIRD PARTY		
13	ADMINISTRATOR.		
14	(3) "CONTRACT" MEANS ANY WRITTEN AGREEMENT BETWEEN A		
	PROVIDER AND A CARRIER FOR THE PROVIDER TO RENDER HEALTH CARE		
	SERVICES TO ENROLLEES OF THE CARRIER.		
10	SERVICES TO ENROLLEES OF THE CARRIER.		
17	(4) "DIAGNOSTIC SERVICES" MEANS ANY MEDICAL OR SURGICAL		
	SERVICE OR PROCEDURE THAT ALLOWS A PROVIDER TO IDENTIFY OR DIAGNOSE A		
	HUMAN DISEASE OR DISORDER.		
17			
20	(5) "ENROLLEE" MEANS ANY PERSON ENTITLED TO HEALTH CARE		
21	BENEFITS FROM A CARRIER.		
22	(6) "HEALTH CARE SERVICES" MEANS A HEALTH OR MEDICAL CARE		
23	3 PROCEDURE OR SERVICE RENDERED BY A PROVIDER THAT:		
24	(I) PROVIDES TESTING, DIAGNOSIS, OR TREATMENT OF A HUMAN		
25	DISEASE OR DYSFUNCTION; OR		
26	(II) DISPENSES DRUGS, MEDICAL DEVICES, MEDICAL APPLIANCES,		
27	OR MEDICAL GOODS FOR THE TREATMENT OF A HUMAN DISEASE OR		
28	DYSFUNCTION.		
29	(7) (1) "PROVIDER" MEANS A PERSON OR ENTITY LICENSED,		
	CERTIFIED, OR OTHERWISE AUTHORIZED UNDER THE HEALTH OCCUPATIONS		
01	ARTICLE OR THE HEALTH - GENERAL ARTICLE TO PROVIDE HEALTH CARE		
32	SERVICES.		
22			
33	(II) "PROVIDER" INCLUDES:		
24	1 A LIEALTH CADE FACTURY.		
34	<del>1. A HEALTH CARE FACILITY;</del>		
35	2  DHADMACY		
33	<del>2. PHARMACY;</del>		
36	3. PROFESSIONAL SERVICES CORPORATION:		
	$\mathcal{I}$		

3 4. PARTNERSHIP: 1 2 5. LIMITED LIABILITY COMPANY; 3 6. PROFESSIONAL OFFICE; OR 7. ANY OTHER ENTITY LICENSED OR AUTHORIZED BY LAW 4 5 TO PROVIDE OR DELIVER PROFESSIONAL HEALTH CARE SERVICES THROUGH OR 6 ON BEHALF OF A PROVIDER. 7 (8) "THERAPEUTIC SERVICES" MEANS ANY MEDICAL OR SURGICAL 8 SERVICE OR PROCEDURE THAT A PROVIDER CAN USE TO TREAT A HUMAN DISEASE 9 OR DISORDER. 10 (B) (1) THIS SECTION APPLIES TO ANY CARRIER THAT PROVIDES HEALTH 11 CARE SERVICES TO ENROLLEES OR OTHERWISE MAKES HEALTH CARE SERVICES 12 AVAILABLE TO ENROLLEES THROUGH CONTRACTS WITH PROVIDERS. 13 (2) THIS SECTION DOES NOT AFFECT THE RIGHT OF AN ENROLLEE TO 14 APPEAL ANY ADVERSE DECISION BY A CARRIER THROUGH THE CARRIER'S APPEALS 15 PROCESS. (C) (1) A CARRIER SHALL DISCLOSE TO PROVIDERS, ENROLLEES, AND 16 17 PROSPECTIVE ENROLLEES THE CARRIER'S DEFINITION OF "EXPERIMENTAL 18 MEDICAL CARE", AS REQUIRED UNDER PARAGRAPH (2) OF THIS SUBSECTION. 19 (2) THE CARRIER SHALL DISCLOSE THE DEFINITION IN: 20 (I) CONTRACTS OFFERED TO PROVIDERS THAT MAY RENDER 21 DIRECT HEALTH CARE SERVICES TO THE ENROLLEES OF THE CARRIER: AND 22 (II) MARKETING MATERIALS AND ENROLLMENT MATERIALS OF 23 THE CARRIER THAT ARE PROVIDED TO CURRENT ENROLLEES AND PROSPECTIVE 24 ENROLLEES. 25 (3) THE DEFINITION SHALL INCLUDE THE GENERAL CRITERIA AND 26 PROCESS THAT THE CARRIER FOLLOWS FOR INDIVIDUAL ENROLLEES OR FOR THE 27 ENTIRE ENROLLED POPULATION IN EVALUATING WHETHER EMERGING MEDICAL 28 AND SURGICAL TREATMENTS WILL BE COVERED OR PAID FOR BY THE CARRIER. 29 (4) THE DEFINITION SHALL BE BINDING ON THE CARRIER. ENROLLEES. 30 AND PROVIDERS FOR THE PURPOSE OF RESOLVING DISPUTES THAT ARISE OVER 31 WHETHER A MEDICAL OR SURGICAL TREATMENT IS OR IS NOT EXPERIMENTAL. 32 AND THEREFORE, COVERED AND PAID FOR BY THE CARRIER. 33 (D) (1) EACH CARRIER SHALL ESTABLISH A SYSTEMATIC, SCIENTIFIC 34 PROCESS TO FOLLOW FOR EVALUATING EMERGING MEDICAL AND SURGICAL 35 TREATMENTS TO ENSURE THAT PROVIDERS AND ENROLLEES HAVE ACCESS TO THE 36 LATEST APPROPRIATE TREATMENTS.

## 37 (2) THE PROCESS SHALL INCLUDE:

38 (I) ONGOING ANALYSES BY THE MEDICAL DIRECTOR OF THE
 39 CARRIER AND THE MEDICAL POLICY STAFF OF THE CARRIER OF PUBLISHED,

1 PEER-REVIEWED MEDICAL LITERATURE, AND THE FINDINGS AND PUBLICATIONS 2 OF STATE AND FEDERAL AGENCIES: AND (II) ONGOING DIALOGUE WITH EXPERTS IN THE LOCAL MEDICAL 3 4 COMMUNITY FOR THE PURPOSE OF EVALUATING WHETHER NEW MEDICAL OR 5 SURGICAL TREATMENTS HAVE BECOME AN APPROPRIATE STANDARD OF CARE FOR 6 SPECIFIED HUMAN DISEASES OR DISORDERS. (3) (I) THE CARRIER SHALL IDENTIFY LEADING LOCAL CLINICAL 8 EXPERTS IN RECOGNIZED MEDICAL AND SURGICAL SPECIALTIES AND 9 SUBSPECIALTIES FOR THE PURPOSE OF HAVING THE CLINICAL EXPERTS PROVIDE 10 THE CARRIER WITH DIALOGUE ON AND ANALYSES OF THE STATUS OF EMERGING 11 MEDICAL AND SURGICAL TREATMENTS. 12 (II) THE CLINICAL EXPERTS SHALL BE DRAWN FROM: 13 1. THE UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE; 2. THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE; 14 15 **3. THE NATIONAL INSTITUTES OF HEALTH;** 16 4. LOCAL PROVIDERS WHO ARE GENERALLY RECOGNIZED 17 AS AUTHORITATIVE RESOURCES ON CERTAIN HUMAN DISEASES AND DISORDERS: 18 AND 5. LOCAL CHAPTERS OF MEDICAL AND SURGICAL 19 20 SPECIALTY SOCIETIES AND PROFESSIONAL ASSOCIATIONS, AS RECOGNIZED BY THE 21 AMERICAN BOARD OF MEDICAL SPECIALTIES AND THE U.S. COUNCIL ON MEDICAL 22 SPECIALTIES 23 (4) THE LOCAL CLINICAL EXPERTS IDENTIFIED BY THE CARRIER SHALL 24 BE: (I) ACTIVELY INVOLVED IN THE PROVISION OF DIRECT HEALTH 25 26 CARE SERVICES TO PATIENTS WITH THE HUMAN DISEASES OR DISORDERS BEING 27 EVALUATED WHETHER OR NOT THE PATIENTS ROUTINELY TREATED BY THE 28 PROVIDER ARE ENROLLEES OF THE CARRIER; 29 (II) BOARD-CERTIFIED IN THE PERTINENT OR APPROPRIATE 30 SPECIALTY OR SUBSPECIALTY AREA: AND 31 (III) GENERALLY RECOGNIZED BY THEIR PEERS TO BE 32 AUTHORITATIVE RESOURCES IN THE CLINICAL AREA BEING EVALUATED. AS 33 EVIDENCED BY FACULTY APPOINTMENTS, AUTHORSHIP OF A SIGNIFICANT BODY OF 34 PEER REVIEWED CLINICAL LITERATURE IN THE RELEVANT SPECIALTY AREA, AND 35 A DEMONSTRATED HISTORY OF LEADERSHIP IN LOCAL, STATE, AND NATIONAL 36 PROFESSIONAL ASSOCIATIONS AND NONPROFIT PATIENT AND COMMUNITY 37 ADVOCACY ORGANIZATIONS THAT ADDRESS THE DISEASES AND SPECIALTY AREAS 38 IN QUESTION.

39 (5) THE CARRIER SHALL IDENTIFY THE LOCAL CLINICAL EXPERTS
 40 WITH WHOM IT CONSULTS:

 1
 (I) UPON THE REQUEST OF AN ENROLLEE, PROVIDER, OR STATE

 2 OFFICIAL; AND

3 (II) ANNUALLY IN ITS DISCLOSURE FILING WITH THE 4 COMMISSIONER.

5 (6) THE CARRIER SHALL DISCLOSE IN ITS FILING WITH THE
 6 COMMISSIONER ANY HONORARIA OR OTHER FEES PAID TO CLINICAL EXPERTS FOR
 7 THEIR SERVICES.

8 (E) A CARRIER'S DECISION TO PAY FOR EMERGING MEDICAL AND SURGICAL
 9 TREATMENTS SHALL RESULT FROM THE CONSENSUS OF OPINION FROM ITS OWN
 10 ANALYSIS AND THE KNOWLEDGE PROVIDED TO THE CARRIER FROM LOCAL
 11 CLINICAL EXPERTS.

(F) (1) EACH CARRIER AND THE LOCAL CLINICAL EXPERTS IDENTIFIED BY
 THE CARRIER SHALL JOINTLY DECIDE THE APPROPRIATE PATIENT SELECTION
 CRITERIA FOR EMERGING MEDICAL AND SURGICAL TREATMENTS FOR THE
 CARRIER'S AND THE LOCAL EXPERT'S REVIEW AND FOR WHICH COVERAGE AND
 PAYMENT IS EXTENDED.

(2) A CARRIER MAY USE THE PATIENT SELECTION CRITERIA AND
 OTHER GUIDELINES JOINTLY AGREED ON WITH THE LOCAL CLINICAL EXPERTS TO
 APPROVE OR DENY COVERAGE AND PAYMENT FOR EMERGING MEDICAL AND
 SURGICAL TREATMENTS FOR ENROLLEES.

(G) (1) A CARRIER'S MEDICAL DIRECTOR AND MEDICAL POLICY STAFF
 MAY NOT MAKE COVERAGE AND PAYMENT DECISIONS ON LIFESAVING EMERGING
 MEDICAL AND SURGICAL TREATMENTS WITHOUT FIRST CONSULTING THE LOCAL
 CLINICAL EXPERTS IDENTIFIED BY THE CARRIER.

25 (2) WHENEVER A CARRIER'S MEDICAL DIRECTOR OR MEDICAL POLICY
 26 STAFF AND THE LOCAL CLINICAL EXPERTS IDENTIFIED BY THE CARRIER DISAGREE
 27 ON COVERAGE AND PAYMENT DECISIONS, THE OPINION OF THE LOCAL CLINICAL
 28 EXPERTS SHALL PREVAIL:

(3) A CARRIER SHALL HAVE THE RIGHT TO REEVALUATE AREAS OF
 DISPUTE BETWEEN THE CARRIER AND THE IDENTIFIED LOCAL CLINICAL EXPERTS
 ANNUALLY TO DETERMINE WHETHER SCIENTIFIC ADVANCES WARRANT A CHANGE
 IN THE CARRIER'S COVERAGE AND PAYMENT POLICY FOR EMERGING MEDICAL
 AND SURGICAL TREATMENTS.

34 (H) (1) EACH YEAR EACH CARRIER SHALL FILE WITH THE COMMISSIONER
 35 A DETAILED REPORT ON ALL THE CLINICAL AREAS AND DIAGNOSTIC AND
 36 THERAPEUTIC SERVICES THAT WERE EVALUATED IN CONSULTATION WITH LOCAL
 37 CLINICAL EXPERTS IDENTIFIED BY THE CARRIER DURING THE PAST YEAR.

38 (2) THE REPORT SHALL INCLUDE:

39 (I) A SUMMARY DESCRIPTION OF EACH CLINICAL ISSUE OR
 40 DIAGNOSTIC OR THERAPEUTIC SERVICE THAT WAS EVALUATED;

(II) FOR EACH DIAGNOSTIC OR THERAPEUTIC SERVICE. A 1 2 SUMMARY OF THE FINDINGS OF THE CARRIER AND THE LOCAL CLINICAL EXPERTS 3 FROM THE REVIEW OF PUBLISHED, PEER REVIEWED MEDICAL LITERATURE: (III) FOR EACH DIAGNOSTIC OR THERAPEUTIC SERVICE, A 4 5 SUMMARY OF THE OPINIONS OF THE LOCAL CLINICAL EXPERTS ON WHETHER THE 6 DIAGNOSTIC OR THERAPEUTIC SERVICE IS CONSIDERED A STANDARD OF CARE FOR 7 THE LOCAL COMMUNITY: 8 (IV) THE NAMES AND AFFILIATIONS OF EACH LOCAL CLINICAL 9 EXPERT WHO WORKED WITH THE CARRIER TO EVALUATE THE DIAGNOSTIC OR 10 THERAPEUTIC SERVICE AND THE FEES OR HONORARIA. IF ANY, THE EXPERT WAS 11 PAID: 12 (V) THE NAMES AND TITLES OF EACH OF THE CARRIER'S 13 EMPLOYEES WHO EVALUATE EMERGING MEDICAL AND SURGICAL TREATMENTS TO 14 DETERMINE WHETHER THESE SERVICES OR PROCEDURES SHOULD BE COVERED 15 AND PAID FOR BY THE CARRIER; 16 (VI) THE NAMES AND AFFILIATIONS OF ANY OUTSIDE 17 CONSULTANTS WHO WORKED WITH THE MEDICAL POLICY STAFF OF THE CARRIER 18 DURING THE PAST YEAR TO EVALUATE WHETHER EMERGING MEDICAL AND 19 SURGICAL TREATMENTS SHOULD BE COVERED BY AND PAID FOR BY THE CARRIER: 20 AND (VII) THE NAMES OF EACH STATE AND FEDERAL AGENCY AND 21 22 EACH FOR PROFIT OR NONPROFIT ORGANIZATION, TRADE GROUP, OR 23 TECHNOLOGY COUNCIL THAT CONTRIBUTED TO THE CARRIER'S EVALUATION OF 24 EMERGING MEDICAL AND SURGICAL TREATMENTS TO DETERMINE WHETHER 25 THESE TREATMENTS SHOULD BE COVERED AND PAID FOR BY THE CARRIER. 26 (3) THE COMMISSIONER SHALL: (I) MAKE EACH CARRIER'S REPORT AVAILABLE TO THE PUBLIC 27 28 FOR INSPECTION AND REVIEW; AND (II) PROVIDE A COPY OF A CARRIER'S REPORT TO ANY PERSON 29 30 UPON REQUEST IN A TIMELY MANNER AND AT A REASONABLE COST TO THE 31 PERSON. 32 (I) A CARRIER MAY NOT CONDITION THE SALARY OR BONUS OF AN 33 EMPLOYEE OR CONTRACTED PROVIDER ON THE NUMBER OR KIND OF HEALTH 34 CARE SERVICES THE EMPLOYEE OR CONTRACTED PROVIDER DENIES TO AN 35 ENROLLEE FOR THE PURPOSE OF SAVING MONEY FOR THE CARRIER OR TO MEET 36 THE FINANCIAL GOALS OF THE CARRIER.

37 (J) A CARRIER MAY NOT PREVENT A PROVIDER IT EMPLOYS OR A PROVIDER
 38 WITH WHICH THE CARRIER CONTRACTS TO RENDER HEALTH CARE SERVICES TO
 39 ENROLLEES FROM:

(1) PROVIDING ENROLLEES WITH FULL AND OPEN DISCLOSURE OF ALL 1 2 THE DIAGNOSTIC OR THERAPEUTIC SERVICES THAT MAY BE APPROPRIATE FOR THE 3 ENROLLEE'S PARTICULAR DISEASE OR DYSFUNCTION: (2) PROVIDING ENROLLEES WITH INFORMATION ON WHETHER THE 4 5 CARRIER COVERS AND PAYS FOR EMERGING MEDICAL AND SURGICAL 6 TREATMENTS AND THE BASIS FOR THE CARRIER'S POSITION; AND 7 (3) INFORMING ENROLLEES OF: 8 (I) THE PROCESS THAT THE CARRIER IS REQUIRED TO ESTABLISH 9 AND FOLLOW UNDER THIS SECTION IN EVALUATING EMERGING MEDICAL AND 10 SURGICAL TREATMENTS FOR THE PURPOSE OF DETERMINING WHETHER THE 11 TREATMENTS WILL BE COVERED AND PAID FOR BY THE CARRIER; AND 12 (II) INFORMATION THAT THE CARRIER IS REQUIRED TO DISCLOSE 13 AS REQUIRED UNDER THIS SECTION. 14 (K) (1) WHENEVER A CARRIER CONSULTS WITH OTHER CONSULTANTS OR

ORGANIZATIONS OTHER THAN THE LOCAL CLINICAL EXPERTS IDENTIFIED BY THE
 CARRIER IN SUBSECTION (D) OF THIS SECTION TO EVALUATE EMERGING MEDICAL
 OR SURGICAL TREATMENTS FOR THE PURPOSE OF DETERMINING WHETHER THE
 TREATMENTS SHOULD BE COVERED AND PAID BY THE CARRIER, THE CARRIER
 SHALL DISCLOSE IMMEDIATELY THE NAMES, AFFILIATIONS, AND ADDRESSES OF
 THESE PERSONS TO THE COMMISSIONER AND THE LOCAL CLINICAL EXPERTS
 IDENTIFIED BY THE CARRIER IN THE PERTINENT CLINICAL AREA.

(2) THE INFORMATION REQUIRED TO BE DISCLOSED IN PARAGRAPH (1)
 OF THIS SUBSECTION SHALL BE MADE AVAILABLE TO AN ENROLLEE UPON THE
 REQUEST OF THE ENROLLEE TO THE COMMISSIONER OR THE CARRIER.

(3) IN ADDITION TO THE INFORMATION REQUIRED TO BE DISCLOSED
 UNDER PARAGRAPH (1) OF THIS SUBSECTION, THE CARRIER SHALL PROVIDE THE
 FEES OR SALARIES, IF ANY, PAID BY THE CARRIER TO EACH CONSULTANT OR
 ORGANIZATION.

(L) THIS SECTION DOES NOT APPLY TO ANY COSMETIC OR MEDICALLY
 UNNECESSARY SERVICE OR PROCEDURE THAT TYPICALLY WOULD BE EXCLUDED
 FROM COVERAGE BY THE CARRIER OR OTHER CARRIERS THAT ISSUE OR DELIVER
 CONTRACTS OR POLICIES OF HEALTH INSURANCE IN THE STATE.

(M) EACH CARRIER SHALL INCLUDE IN SUMMARY FORM INFORMATION ON
 THE PROCESS THAT THE CARRIER IS REQUIRED UNDER THIS SECTION TO
 ESTABLISH AND FOLLOW IN EVALUATING EMERGING MEDICAL AND SURGICAL
 TREATMENTS FOR THE PURPOSE OF MAKING COVERAGE AND PAYMENT DECISIONS
 IN:

38 (1) THE MARKETING AND ENROLLMENT MATERIALS OF THE CARRIER
 39 TO EACH CURRENT ENROLLEE AND PROSPECTIVE ENROLLEE AT THE TIME OF OPEN
 40 ENROLLMENT OR RENEWAL; AND

(2) THE CONTRACT OR AN ATTACHMENT TO THE CONTRACT OF A 1 2 PROVIDER BEING OFFERED A CONTRACT BY THE CARRIER TO RENDER HEALTH 3 CARE SERVICES TO ENROLLEES OF THE CARRIER. (N) AFTER NOTICE AND AN OPPORTUNITY FOR A HEARING, A CARRIER THAT 4 5 VIOLATES THIS SECTION IS SUBJECT TO A CIVIL FINE OF \$10,000 FOR A FIRST 6 VIOLATION AND \$25,000 FOR EACH SUBSEQUENT VIOLATION. 7 (O) THE COMMISSIONER MAY ADOPT REGULATIONS TO CARRY OUT THIS 8 SECTION. 9 (a) The Governor shall convene a Task Force on Emerging Medical and Surgical 10 Treatments to: 11 (1) Study insurance coverage of emerging medical and surgical treatments; (2) Examine the processes by which health insurance carriers evaluate 12 13 emerging medical and surgical treatments for coverage; 14 (3) Determine whether and what form of State intervention in health 15 insurers' processes is appropriate; 16 (4) Determine appropriate disclosure of processes for evaluating emerging 17 medical and surgical treatments for health insurance coverage; 18 (5) Evaluate the need for State intervention in communications between 19 health care providers and consumers regarding emerging medical and surgical treatments; 20 and 21 (6) Review any other issues the Task Force considers appropriate pertaining 22 to insurance coverage of emerging medical and surgical treatments. 23 (b) The Task Force shall consist of the following members: 24 (1) Two members of the Senate of Maryland, appointed by the President of 25 the Senate; 26 (2) Two members of the House of Delegates of Maryland, appointed by the 27 Speaker of the House; (3) One representative of the University of Maryland Medical School, 28 29 appointed by the Governor; 30 (4) One representative of The Johns Hopkins University Medical School, 31 appointed by the Governor; 32 (5) One representative of the National Institutes of Health, appointed by 33 the Governor; 34 (6) One representative of the health insurance industry, appointed by the 35 Governor; 36 (7) One representative of a national nonprofit health maintenance

37 organization, appointed by the Governor;

## SENATE BILL 204

1 2	designee;	(8) The Secretary of Health and Mental Hygiene, or the Secretary's	
3 4	designee; and	(9) The Maryland Insurance Commissioner, or the Commissioner's	
5		(10) Two members of the public, appointed by the Governor.	
6 7	(c) The <u>members.</u>	e Governor shall select a Chairman of the Task Force, from among its	
8 9 10	Governor and subject to § 2-1312 of the State Government Article, the General Assembly		
10	•	(ON 2. AND BE IT FURTHER ENACTED, That this Act shall take effect	

12 October July 1, 1996. It shall remain effective for a period of 1 year and, at the end of

13 June 30, 1997, with no further action required by the General Assembly, this Act shall be

14 abrogated and of no further force and effect.